PuriCore Share Price (PURI)

30.50 0.00 (0.00%) delayed: 6:30PM GMT
Bid price 30.00 Open price 30.50
Ask price 31.00 Prev close 30.50
High price 30.02 Spread 3.23%
Low price 30.02 Volume 6,666

Register now for FREE live PuriCore share prices, PuriCore stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get PuriCore Level 2 Data, indepth research tools and investor commentary for PuriCore (PURI) and other London Stock Exchange equities.

PuriCore Share Price Chart

Advanced Charts >>

Register now for FREE PuriCore share price charts

PuriCore Share Price Information

Name PuriCore Epic PURI
Sector Health Care Equipment & Services ISIN GB00B3XBCR18
Activites PuriCore develops and commercializes proprietary products that safely, effectively, and naturally kill contagious pathogens including major public health threats—M.tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and Legionella. Our products generate hypochlorous acid, the same natural anti-microbial produced by the human body to fight pathogens. Hypochlorous acid is highly effective in killing all types of bacteria, viruses, and fungal spores. PuriCore's technology and solutions are used in a broad range of markets that depend upon controlling contamination, including endoscopy, food retail, foodservice, hospitality, institutional, and wound therapy. Our antimicrobial solution is deployed as soaks, sprays, mists, and in other forms to limit the spread of infectious disease. The patented technologies use a simple combination of water, salt, and electricity to produce the same powerful solution found in the human immune system. PuriCore's highly sophisticated processes and controls allow the production of these unique biocidal solutions with a variety of different chemical and microbiological properties for use in specific settings and applications. Index n/a

PuriCore Key Numbers

Latest Share Price (p) 30.50 Net Gearing (%) 35.86
Market Capitalisation (£m) 15.29 Gross Gearing (%) 49.05
Shares in issue (m) 50.14 Debt Ratio 0.00
P/E Ratio -2.35 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.96
Dividend Yield (%) 0.00 Price to book value 1.15
Dividend cover (x) 0.00 ROCE -0.03
Earning per share (p) -13.00 EPS Growth (%) -225.00
52 week high / low 54.50 / 27.50 DPS Growth (%) n/a

PuriCore Director Deals

Dec.Date Type Director Pos No. of Shares
12/08/2014 BUY Michael Ashton CEO 50,000
12/08/2014 BUY Michael Ashton CEO 100,000
01/11/2013 BUY Daniel Hegglin NED 1,000,000
06/09/2013 BUY Daniel Hegglin NED 50,000
06/09/2013 BUY Daniel Hegglin NED 550,000

More PuriCore Director Deals >>

PuriCore Company News

07:43 24/02/2015

PURI sees sizeable fall in results due to directional shift

PuriCore said directional changes in the business have yielded a sizeable decline in financial results, but it remains confident the strategies being implemented will provide greater sustainable shareholder value in the longer term. CEO Michael Ashton 2014 was a year of significant change for...

07:13 24/02/2015

FLASH: PURI sees sizeable fall in results due to directional shift

Story provided by StockMarketWire.com

07:00 24/02/2015

Trading Update

/* */ RNS Number : 6633F PuriCore Plc 24 February 2015    PuriCore plc ("PuriCore" or the "Company") Trading Update   A year of significant change     24 February 2015 -   PuriCore plc   (AIM: PURI), an...

More PuriCore Company News >>

Register now for FREE PuriCore company news

PuriCore Share Price Discussions

2 months ago

PuriCore plc (PURI)

PuriCore specializes in developing and commercializing solutions to protect against the spread of infectious pathogens. Our proprietary products are effective while being completely safe for human and animal health and the environment. PuriCore has broad experience in key markets that...

more than 1 year ago

Puricore - US FDA approval and US Supermarket interest (PURI)

This one has come to my attention after a sudden surge from the bottom of its price range. In the last two weeks, PURI has announced US FDA approval to market its Sterilox Endoscopy High-Level Disinfectant System as a medical device in the US; also announced first prelims showing increasing...

Register now for FREE PuriCore share price discussions